www.tidesoffortune.fora.pl

cheapbag214s

Cempra Inc. to develop pediatric antibiotic
CHAPEL HILL, N.C., May 28 () -- A U.S. contract to develop a fourth-generation macrolide antibiotic to combat pediatric infections and bio-terror threat pathogens has been given to Cempra Inc.Cempra, a clinical-stage pharmaceutical company that focuses on developing differentiated antibiotics,[url=http://www.christianslouboutinsales.com]Christian Louboutin Outlet Online[/url], said the $58 million contract was issued by the Biomedical Advanced Research and Development Authority and is for a maximum period of five years.The company's lead candidate for the antibiotic is solithromycin, which is in Phase 3 development for community-acquired bacterial pneumonia in adults."We are delighted that BARDA has recognized solithromycin as a potentially safe and effective treatment for the pediatric population," said Prabhavathi Fernandes, chief executive officer of Cempra. "Macrolides have traditionally been favored for use in pediatrics because of their safety and efficacy."Solithromycin's approval would be the first orally administered antibiotic approved in decades ... (and) we view BARDA's funding of this project as recognition of the potential of solithromycin to have broad utility in all age groups."Cempra said the initial performance period of the contract is two years, with guaranteed funding $17.7 million. Options are featured to extend the base award to five years with a total contract to $58 million."The contract is expected to fund a variety of activities that are planned to lead to the Pediatric as well as the Animal Rule New Drug Applications for use of solithromycin against bioterror threat pathogens," Cempra said.